Nampt-inhibitor-based chemopotentiating effects on breast cancer cells / 中华内分泌外科杂志

Objective To study the expression of nicotinamide phosphoribosyl transferase (Nampt) in breast cancer and to investigate the effects of Nampt inhibitor on the growth and chemotherapy sensitivity of breast cancer cells.Methods Nampt mRNA expression in breast cancer tissues and adjacent normal tissues was detected by qRT-PCR method.The effect of Nampt inhibitor on the growth of breast cancer cells and chemotherapy sensitization was detected by MTT and soft agar clonogenic assays.Results Nampt in breast cancer was significantly higher than that in normal breast tissue (P=0.000).Nampt inhibitor FK866 repressed breast cancer cell proliferation (24 h,P=0.003;48 h,P=0.001) and suppressed cell anchorage-independent growth (0.3 nM vs 0 nM,P=0.02;3 nM vs 0.3 nM,P=0.0143;0 nM vs 3 nM,P=0.02).FK866 also increased the chemo-sensitivity of breast cancer cells to fluorouracil by greater inhibition of cell proliferation.Conclusion Our findings indicate that Nampt may be a new therapeutic target for breast cancer.

Comparison of immunohistochemistry and fluorescence in situ hybridization in detecting c-erbB-2 expression in breast cancer / 西安交通大学学报(医学版)

Objective To compare the consistency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in detecting c-erbB-2 status in breast cancer tissues. Methods A total of 50 breast cancer paraffin embedded samples were selected, of which there were 10 cases of c-erbB-2 protein expression (+), 20 cases of (++) and 20 cases of (+++). FISH was used to assess the amplification of c-erbB-2 gene, and SPSS 13.0 software was employed to analyze the difference and consistency between the two methods. Results IHC and FISH methods had a good consistency when detecting c-erbB-2 (+) and (+++) expressions in breast cancer tissues, with the coincidence rate of 89.2%. However, when IHC was used to test c-erbB-2 (++), the result of FISH was quite different, with the coincidence rate of only 35.3%. Conclusion IHC is a preliminary method to detect c-erbB-2 status in breast cancer. IHC and FISH methods have a good consistency in detecting c-erbB-2 (+) and (+++) status in breast cancer tissues. As detection of c-erbB-2 (++) with IHC has a different result from FISH, such patients should receive FISH confirmation for herceptin therapy.